| Literature DB >> 19811624 |
Liesbeth Borgermans1, Geert Goderis, Carine Van Den Broeke, Geert Verbeke, An Carbonez, Anna Ivanova, Chantal Mathieu, Bert Aertgeerts, Jan Heyrman, Richard Grol.
Abstract
BACKGROUND: Type 2 diabetes mellitus is a complex, progressive disease which requires a variety of quality improvement strategies. Limited information is available on the feasibility and effectiveness of interdisciplinary diabetes care teams (IDCT) operating on the interface between primary and specialty care. A first study hypothesis was that the implementation of an IDCT is feasible in a health care setting with limited tradition in shared care. A second hypothesis was that patients who make use of an IDCT would have significantly better outcomes compared to non-users of the IDCT after an 18-month intervention period. A third hypothesis was that patients who used the IDCT in an Advanced quality Improvement Program (AQIP) would have significantly better outcomes compared to users of a Usual Quality Improvement Program (UQIP).Entities:
Mesh:
Year: 2009 PMID: 19811624 PMCID: PMC2762969 DOI: 10.1186/1472-6963-9-179
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
CONSORT Checklist of items of cluster randomized trials.
| 1 | → Interdisciplinary Diabetes Care Teams operating on the interface between primary and specialty care are associated with improved outcomes of care: Findings from the Leuven Diabetes Project. | |
| 2 | → Scientific background and explanation of rationale: see Background section | |
| 3 | → All 379 primary care physicians (PCP's) that actively execute their profession in the project region were invited to participate. | |
| Interventions | 4 | → See methods section |
| Objectives | 5 | → See methods section |
| Outcomes | 6 | → The primary endpoints of the study were the proportion of patients reaching three clinical ADA-targets: (1) HbA1c < 7%; (2) SBD ≤ 130 mm Hg; (3) LDL-C < 100 mg/dl. Secondary endpoints were the mean improvements in individual parameters of 12 validated parameters, i.e. HbA1c, LDL-C, HDL-C, Total Cholesterol, SBP, Diastolic Blood Pressure (DBP), weight, physical exercise, healthy diet, smoking status, statin and anti-platelet therapy. |
| Sample size | 7 | → The financer to the project imposes a sample size of minimal one third of the potential PCP's. Using the calculator of the university of Aberdeen, sample size for cluster trials was computed. With a significance level of 0.05 and assumed Intra Cluster Coefficient of 0.1, we calculated that 114 clusters with a cluster size of 20 gave 80% power to detect between AQIP and UQIP a 10% in the absolute difference in the proportion of patients achieving a 10% improvement in the primary biochemical endpoints. Based on the fitted mixed models the observed ICC values are: HBA1C: 0.0445, SBD: 0.0466, LDL Cholesterol: 0.0399. |
| Randomization | 8 | → After the recruitment period, using computer-generated numbers, a researcher not involved the study and blind to the identity of the practices will perform a randomization stratified by practice size (solo/duo/group practice) and the presence/absence of an electronic medical recording system. |
| Allocation concealment | 9 | → Program Manager - invitation, stratified. |
| Implementation | 10 | → Allocation: Van Den Broeke Carine, researcher to the scientific team, |
| Blinding (masking) | 11 | → No blinding was possible at physician level, (both groups presented as 'intervention'), but patients didn't know to which intervention arm their physician belonged. |
| Statistical methods | 12 | → See methods section, sub-heading statistical analysis. |
Interventions for UQIP versus AQIP (patient).
| Medical assessments and education upon referral of the PCPs by diabetologist or Diabetes Care Team | Medical assessments and education upon referral of the PCPs by diabetologist or Diabetes Care Team | |
| ---- | Education of patients in practice (by flying educator) | |
| ---- | Education at patient's home (by flying educator) | |
| ---- | Counseling by health psychologist | |
| ---- | Structured educational materials from IDCT | |
| ---- | Structured educational materials from community organizations | |
| ---- | Group educational sessions for patients and family members | |
| ---- | Free access to blood monitoring tools for self-management | |
Interventions for UQIP versus AQIP (professional).
| Distribution of treatment protocol | Distribution of treatment protocol | |
| Two post-graduate educational sessions | Four post-graduate educational sessions provided by diabetologist (opinion leader): | |
| - Evidence based guidelines | Evidence-based guidelines and principles of shared care | |
| - The use of insulin | The use of insulin | |
| Patient-centered counseling | ||
| Peer review | ||
| Standard educational materials | Extended educational materials | |
| ---- | Inviting PCPs during IDCT meetings to discuss patient cases | |
| ---- | Providing structured communication forms to PCPs by IDCT | |
| ---- | Distribution of shared care protocol + referral indication | |
| At start and end of project: summary of clinical performance | Every 3 months: summaries of clinical performance | |
| ---- | Every three months: benchmarking feed-back | |
| Clinical reminders at start and end of project | Every three months: Clinical reminders | |
| ---- | Every three months: Shared care reminders | |
Interventions for UQIP versus AQIP (organisational).
| Interdisciplinary Diabetes Care Team (IDCT) operating close to regular care | Active installment of Interdisciplinary Diabetes Care Team (IDCT) operating under supervision of a diabetologist from a University Hospital | |
| Diabetes Program manager providing logistic support to PCPs | ||
| ---- | Introduction of shared care protocol | |
| Active encouragement by IDCT and scientific team of PCPs to use shared care protocol | ||
| ---- | Referral arrangements | |
| ---- | Liaison activities by IDCT towards in-hospital diabetes care team in secondary care | |
| ---- | Involvement of independent pharmacists | |
| Quality Assurance Team | Quality Assurance Team | |
Figure 1Flowchart displaying Enrollment of patients and physicians in the study.
Baseline information in users and non-users of the IDCT.
| Mean age (years) | 62.3 (11.5) | 68.5 (11.6) | <0.0001 |
| Mean diabetes duration (years) | 6.5 (6.7) | 7.3 (7.1) | 0.0674 |
| Female gender (%) | 46 | 52 | 0.0001 |
| HbA1c (%) | 7.8 (1.6) | 7.1 (1.2) | <0.0001 |
| SBP (mm Hg) | 136 (16) | 136 (16) | 0.8012 |
| DBP (mm Hg) | 81.2 (8.6) | 79.3 (8.9) | 0.0002 |
| T. Chol (mg/dl) | 197 (39) | 191 (41) | 0.0223 |
| LDL-C (mg/dl) | 111 (32) | 108 (34) | 0.1181 |
| HDL-C (mg/dl) | 53 (16) | 54 (15) | 0.4763 |
| BMI | 30.4 (5.3) | 29.5 (5.3) | 0.0087 |
| Duration of insulin therapy | 6.2 (7.3) | 7.9 (7.6) | 0.1820 |
| Low education level (%) | 40 | 50 | 0.0002 |
| High education level (%) | 20 | 17 | 0.0669 |
| HbA1c < 8% | 62 | 84 | <0.0001 |
| HbA1c < 7% | 37 | 57 | <0.0001 |
| SBP ≤ 130 (mm Hg) | 48 | 50 | 0.4892 |
| LDL-C < 100 (mg/dl) | 36 | 42 | 0.0621 |
| Non smoker (%) | 88 | 85 | 0.3332 |
| Healthy Diet (%) | 63 | 67 | 0.1201 |
| Physical Exercise (%) | 59 | 52 | 0.3597 |
| Aspirin/clopidogrel (%) | 35 | 37 | 0.0952 |
| ACE/A2A treatment (%) | 31 | 34 | 0.1945 |
| Statin (%) | 37 | 40 | 0.3424 |
| Metformin if obesity (%) | 71 | 58 | 0.0008 |
| Insulin (%) | 16 | 20 | 0.1063 |
| Complications (microangiopathic) | 86 | 71 | 0.1351 |
Baseline information in users of the IDCT for UQIP and AQIP.
| HbA1c (%) | 7,72 (1.62) | 7,98 (1.59) | 0.2632 |
| SBP (mm Hg) | 135,35 (15.28) | 138,85 (19.09) | 0.1752 |
| DBP (mm Hg) | 80,69 (8.52) | 82,62 (8.72) | 0.3202 |
| TCHoL (mg/dl) | 193,96 (39.51) | 204,01 (38.25) | 0.0494 |
| LDL CHol (mg/dl) | 108,94 (32.56) | 115,19 (31.09) | 0.2304 |
| HDL CHol (mg/dl) | 53,43 (15.83) | 53.51 (15.61) | 0.9089 |
| BMI | 30,49 (5.22) | 30,17 (5.52) | 0.5399 |
| Targets reached (%) | 85 | 75 | 0.1324 |
| Smokers (%) | 88,35 | 85,9 | 0.5571 |
| Healthy diet (%) | 62,36 | 63,89 | 0.8570 |
| Physical exercise (%) | 55,07 | 69,23 | 0.0477 |
| Aspirin/clopidogrel (%) | 36,56 | 37,21 | 0.7233 |
| ACE/A2A treatment (%) | 68,72 | 65,12 | 0.4532 |
| Statin treatment (%) | 40,09 | 27,91 | 0.0391 |
Use of IDCT services by PCPs and patients in UQIP and AQIP.
| IDCT consultations | 87 patients (9.5%) referred by 40 PCPs (75%) | 226 patients (14.3%) referred by 61 PCPs (91%) |
| Educator in primary care facility | 38 patients (4.1%) | 107 patients (6.8%) |
| Educator at home or in PCP practice | NA | 40 patients (2.5%) |
| Dietician | 40 patients (4.3%) | 138 patients (8.7%) |
| Internal medical doctor | 29 patients (3.1%) | 79 patients (5.0%) |
| Opthalmologist | 19 patients (2.1%) | 55 patients (3.5%) |
| Health psychologist | NA | 18 patients (1.1%) |
| Printed educational materials for patients | NA | 126 distributed |
| Communication forms to PCPs | NA | 924 reports |
| Free blood monitoring tools for patients with insulin therapy onset | NA | 107 distributed |
| Group information sessions for patient and family | NA | 7 sessions, 310 participants from 14 physicians |
Evolution of variables in all patients (T0: baseline value, T1: value after 18 months of intervention) and IDCT use/non-use.
| HbA1c (%) | 7.15 (1.26) | 6.76 (0.95) | -0.39 | <0.0001 |
| IDCT users | 7.78 (1.63) | 7.00 (1.09) | -0.78 | <0.0001 |
| IDCT non-users | 7.05 (1.16) | 6.72 (0.92) | -0.33 | |
| SBD (mm Hg) | 136 (16) | 133 (15) | -3 | <0.0001 |
| IDCT users | 136 (16) | 133 (15) | -3 | 0.6335 |
| IDCT non-users | 136 (16) | 133 (15) | -3 | |
| DBD (mm Hg) | 79 (9) | 77 (9) | -2 | <0.0001 |
| IDCT users | 81 (9) | 79 (9) | -2 | 0.6103 |
| IDCT non-users | 79 (9) | 77 (9) | -2 | |
| Tchol (mg/dl) | 192 (40) | 177 (37) | -5 | <0.0001 |
| IDCT users | 196 (39) | 173 (38) | -23 | 0.0002 |
| IDCT non-users | 192 (41) | 177 (37) | -15 | |
| HDL-C (mg/dl) | 54 (16) | 55 (15) | +1 | 0.0006 |
| IDCT users | 54 (16) | 55 (16) | +1 | 0.8242 |
| IDCT non-users | 54 (15) | 55 (15) | +1 | |
| LDL-C (mg/dl) | 108 (34) | 95 (32) | -13 | <0,0001 |
| IDCT users | 110 (32) | 90 (33) | -20 | 0.0012 |
| IDCT non-users | 108 (34) | 95 (32) | -13 | |
| BMI (kg/m2) | 29.6 (5.3) | 29.3 (5.2) | -0.3 | <0,0001 |
| IDCT users | 30.3 (5.4) | 30.0 (5.3) | -0.3 | 0.9737 |
| IDCT non-users | 29.5 (5.2) | 29.2 (5.2) | -0.3 | |
| Hba1c < 7%, | 54% | 67% | +13% | <0.0001 |
| IDCT users | 37% | 57% | +20% | 0.07449 |
| IDCT non-users | 57% | 69% | +12% | |
| BMI < 25 kg/m2 | 18% | 20% | +2% | 0.00108 |
| IDCT users | 15% | 18% | +3% | 0.7186 |
| IDCT non-users | 19% | 21% | +2% | |
| Non smokers | 86% | 89% | +3% | 0.023 |
| IDCT users | 88% | 89% | +1% | 0.2675 |
| IDCT non-users | 85% | 89% | +4% | |
| Healthy nutrition | 67% | 75% | +8% | <0.0001 |
| IDCT users | 63% | 77% | + 4% | 0.9885 |
| IDCT non-users | 67% | 75% | +8% | |
| Physical exercise | 53% | 60% | +7% | 0.00035 |
| IDCT users | 59% | 71% | +12% | 0.3349 |
| IDCT non-users | 52% | 59% | +7% | |
| Aspirin/clopidogrel | 40% | 57% | +17% | <0.0001 |
| IDCT users | 37% | 67% | +30% | 0.005644 |
| IDCT non-users | 40% | 56% | +16% | |
| ACE/A2A | 73% | 78% | +5% | <0.0001 |
| IDCT users | 68% | 76% | +8% | 0.3954 |
| IDCT non-users | 74% | 78% | +4% | |
| Statins | 39% | 53% | +14% | <0.0001 |
| IDCT users | 37% | 57% | +20% | 0.04431 |
| IDCT non-users | 40% | 53% | +13% | |
Figure 2Proportions of patients reaching therapeutic targets in users and non-users of the IDCT. N = total number of included patients in the different subgroups. IDCT+ = group of patients who have consulted the IDCT and who presented with values of all three primary outcome parameters. IDCT- = group of patients who have not consulted the IDCT and who presented with values of all three primary outcome parameters.
Effect of IDCT use in AQIP compared to UQIP*.
| HbA1c (%) | 0.0848 | 0.1476 | 0.5656 |
| SBP (mm Hg) | 2.3901 | 2.2566 | 0.2896 |
| DBP (mm Hg) | 0.4532 | 1.3308 | 0.7335 |
| T. Chol (mg/dl) | 1.8074 | 5.379 | 0.7369 |
| LDL-CL (mg/dl) | 0.1833 | 4.686 | 0.9688 |
| HDL-C (mg/dl) | -1.4947 | 1.4404 | 0.2995 |
| BMI | 0.0092 | 0.2799 | 0.9737 |
| Targets (%) | -0.3404 | 0.4078 | 0.4039 |
| Non smoker (%) | 1.0710 | 1.3691 | 0.4341 |
| Health diet (%) | 0.4817 | 0.6984 | 0.4904 |
| Physical exercise (%) | 1.0129 | 0.6550 | 0.1221 |
| Aspirin/clopidogrel (%) | 1.3368 | 0.5702 | 0.0119 |
| ACE/A2A treatment (%) | 1.4285 | 0.7558 | 0.0584 |
| Statin treatment (%) | 0.2726 | 0.6341 | 0.1766 |
* Reported estimates represent the difference of the effect of IDCT use on each outcome in the AQIP group and the effect of IDCT use in the UQIP group.